About this course
Quality and technical personnel need to be informed and aware of pharmaceutical legislation. Changes in legislation and guidelines, and the interpretation of them, can have significant implications for the individual and their company.
This is the continuation of a very successful series of one-day seminars that are designed to form part of your Continuing Professional Development.
What You Will Learn
- USA changes to legislation and FDA guidance
- The reality and interpretation of recent and new EU legislation
- Changes to EU GMPs
- An update on ICH and other international initiatives
- UK updates
Venue
NSF-DBA Boston Office
These courses will take place in NSF-DBA own training facilities
NSF-DBA USA LLC
Training Facility 6th floor
129 South St
Boston MA 02111
For Travel Directions To Our Offices From South Station Please Follow This Link
What you've said
What Previous Attendees Said About this Course in Europe
“It was good to get an independent view from experts and this allowed me to clarify my interpretation of the changes into something realistic at work.”
Adam Haigh, Perrigo UK, UK
“An excellent summary of the current and future state of play in the regulatory arena globally. An essential course for myself as a QP.”
David Preston, Colgate Palmolive (UK), UK
“Very good summary of recent and pending changes. Perfect Viva preparation for trainee QPs.”
David Franks, Reckitt Benckiser Healthcare (UK), UK
“Excellent value for money. Content and delivery very high standard.”
Mark Dignum, Contract QP, UK
“Excellent update of GMP/GDP EU and US legislation and guidance. Especially valuable for active and aspiring QPs in EU.”
Neil Churcher, Astellas Pharma, UK
“A great way to get a good bite sized appreciation of current and planned legislation changes accompanied by a high level of enthusiasm from the presenters!”
Robert Hughes, AstraZeneca Pharmaceuticals, UK
“Excellent summary, delivered professionally as usual. Thanks.”
Daniel Bell, Napp Pharmaceuticals, UK
“Certainly important to keep up-to-date with legislation – will definitely bring this back to site/group as an ongoing requirement in future.”
Michael Kirk, Cara Partners, Republic of Ireland
“Another excellent update session and great opportunity to discuss shared experiences with other QPs – getting views from a broad spectrum of pharma is always very valuable.”
Paul Thomas, Thomas Pharma, UK
“Excellent presentation and opportunity for discussion.”
Steve Collins, Bristol Laboratories, UK
“Keeping pace is becoming difficult as all get busier – this course helps.”
Duncan Fawthrop, Amdipharm, UK
“Being QP registered but based outside EU/UK course enables current updates to ensure information and knowledge is kept current and abreast of upcoming issues and changes.”
Angela Walford, The Biovac Institute, Republic of South Africa
“An excellent round up and update. Something I would not miss as a QP it is needed to keep up to date and a little ahead if possible.”
Richard Brown, Rosemont Pharmaceuticals, UK
An NSF International Company 
